Title
Childhood and adolescent phenol and phthalate exposure and the age of menarche in Latina girls.

Permalink
https://escholarship.org/uc/item/5v8568jz

Journal
Environmental health : a global access science source, 17(1)

ISSN
1476-069X

Authors
Binder, Alexandra M
Corvalan, Camila
Calafat, Antonia M
et al.

Publication Date
2018-04-03

DOI
10.1186/s12940-018-0376-z

Peer reviewed
Childhood and adolescent phenol and phthalate exposure and the age of menarche in Latina girls

Alexandra M. Binder1, Camila Corvalan2, Antonia M. Calafat3, Xiaoyun Ye3, Verónica Mericq4, Ana Pereira2 and Karin B. Michels1*

Abstract

Background: The age of menarche has been associated with metabolic and cardiovascular disease, as well as cancer risk. The decline in menarcheal age over the past century may be partially attributable to increased exposure to endocrine disrupting chemicals (EDCs).

Methods: We assessed the influence of 26 phenol and phthalate biomarkers on the timing of menarche in a longitudinal cohort of Chilean girls. These EDCs were quantified in urine collected prior to the onset of breast development (Tanner 1; B1), and during adolescence (Tanner 4; B4). Multivariable accelerated failure time (AFT) models were used to analyze associations between biomarker concentrations and the age of menarche adjusting for body mass index (BMI) Z-score and maternal education, accounting for within-subject correlation.

Results: Several biomarkers were significantly associated with the age at menarche; however, these associations were dependent on the timing of biomarker assessment. A log(ng/ml) increase in B1 concentrations of di(2-ethylhexyl) phthalate biomarkers was associated with later menarche (hazard ratio (HR): 0.77; 95% CI: 0.60, 0.98), whereas higher B1 concentrations of 2,5-dichlorophenol and benzophenone-3 were associated with earlier menarche (HR: 1.13; 95% CI: 1.01, 1.27; HR: 1.17; 95% CI: 1.06, 1.29, respectively). Elevated B4 concentrations of monomethyl phthalate were similarly associated with earlier menarche (HR: 1.30; 95% CI: 1.10, 1.53). The impact of monoethyl phthalate and triclosan concentrations on pubertal timing were significantly modified by BMI Z-score. Higher monoethyl phthalate and triclosan concentrations were associated with earlier menarche among overweight or obese girls, but not among those that were normal weight.

Conclusions: This study identifies modulation of sexual maturation by specific EDC biomarkers in Latina girls.

Keywords: Menarche, Puberty, Phenols, Phthalates, Endocrine disrupting chemicals

Background

Determinants of pubertal timing are of public health concern because of the association between the age of onset and adult disease susceptibility. Among females, early menarche has been associated with an increased risk of type 2 diabetes, cardiovascular disease, and reproductive cancers, including breast [1–3]. The average age of menarche has decreased from 16-17 years at the end of the nineteenth century, to less than 13 years across Europe and the United States, likely due to improvements in nutrition and general health [4, 5]. While the age of menarche was thought to have stabilized in the past 50 years, more recent studies have suggested that the age of menarche has continued to decline in South America, the United States, and many countries in Europe [6–9]. The secular trend towards earlier menarche has been observed across race/ethnicity groups, despite differences in timing [7, 10–12]. Within the United States, the average age of menarche is earlier among Hispanic and black females relative to white females, adjusting for BMI, as well as social and economic
indicators [7, 13]. Across Europe and South America, the fastest decline has been among impoverished girls, in spite of earlier menarche being previously more common among affluent families [6, 8, 9, 14, 15].

The two primary hypotheses for this shift towards earlier menarche are the growing childhood obesity epidemic and increasing exposure to endocrine disruptor chemicals (EDCs) [16–18]. EDCs can influence the endocrine system through a multitude of mechanisms, including competitive binding to hormone receptors to modulation of hormone synthesis and metabolism [19]. There is building evidence that EDCs can affect proper function across a number of different tissues, including breast tissue and female reproductive organs [19], as well as influencing the neuroendocrine control of reproduction. Results of both in vivo studies and a few longitudinal human cohorts suggest some of these compounds may be obesogenic, with early life exposure associated with childhood body size [20–23]. Phenols and phthalates are two classes of EDCs of particular concern due to their use in an extensive array of products, including plastics, building materials, personal care products, insecticides, and herbicides [24]. In this study, we analyzed the association between prepubescent and pubescent biomarkers of exposure to select phenols and phthalates and the timing of menarche within a longitudinal cohort of Chilean girls born in 2002–2003. Two cross-sectional studies and four longitudinal studies have analyzed the influence of childhood EDC exposure on the age of menarche [25–30]. The results of these studies have been largely discordant, potentially reflecting regional and socioeconomic influences on exposure profile, differences in the age of biomarker measurement, and possible effect modification by race/ethnicity. For this study, we quantified a broad panel of 26 phenol and phthalate urinary biomarker concentrations prior to the onset of breast development (Tanner 1; B1) and at Tanner 4 (B4). This study provides unique insight into the influence of these compounds on pubertal timing in Latina girls.

Methods

Study population

Our study population was a random subset of 200 girls part of the longitudinal Growth and Obesity Cohort Study (GOCS) with urine samples collected at B1 (ages 6.7 to 9.6 years; median age: 7.9 years) and B4 (ages 9.4 to 13.1 years; median age: 11.2 years). The GOCS children were born in 2002–2003, and are representative of the low to middle-income families in Santiago, Chile. A description of the cohort has been provided elsewhere [31]. Starting in 2009, breast development was assessed by two trained dietitians (kappa with pediatric endocrinologist = 0.85) by visual inspection using Tanner’s rating scale approximately every 6 months [32]. Palpation was additionally used to distinguish breast Tanner 1 from Tanner 2. Sex and age-adjusted BMI Z-score at each visit were calculated based on the Centers for Disease Control and Prevention (CDC) growth charts. Girls were categorized as having excess weight (overweight or obese) if their BMI Z-score was equal or above the 85th percentile. Informed consent was obtained from all parents or guardians of children before the start of data collection.

Biomarker measurements

Fasting spot urine samples were collected between 10 AM and 12 PM in polypropylene sterile cups, and were immediately vortexed and aliquoted. Concentrations of 26 phenol and phthalate biomarkers were quantified in urines collected at breast Tanner 1 (B1) and Tanner 4 (B4) from 200 girls (400 samples). The analytical measurements were performed at the CDC National Center for Environmental Health Laboratory using previously described analytical methods [33, 34]. Concentrations below the limit of detection (LOD) were given an imputed value equal to LOD/sqrt(2) [35]. Biomarker concentrations (ng/ml) were corrected for specific gravity. Dilution adjustment was performed using the formula \( P_c = P \times \frac{1.015 - 1}{SG - 1} \), where \( P_c \) is the specific gravity-corrected biomarker concentration, \( P \) is the observed biomarker concentration, SG is the specific gravity of the urine sample, and 1.015 is the median SG of the study population [36, 37]. To calculate the summation of di(2-ethylhexyl) phthalate (DEHP) metabolites (DEHP), concentrations of MEHP, MEOHP, MEHHP, and MECPP were converted to nmol/L before being added together. The analysis of blinded specimens by the CDC laboratory was determined not to constitute engagement in human subjects’ research.

Age of menarche

Prior to the onset of B4, girls were asked to report the date of their first menstrual bleeding at each 6-month visit. After achieving B4, girls were contacted by study dieticians every 3 months to survey whether the girl had reached menarche. During this phone interview, a questionnaire was used to differentiate menarche from other potential causes of vaginal bleeding, such as vaginal infection, urinary infection or trauma. Longitudinal follow-up of participants enabled the confirmation of menarche onset.

Statistical methods

Multivariable accelerated failure time (AFT) models were used to assess the influence of individual phenol and phthalate biomarker concentrations on time to menarche, assuming a Weibull distribution. To account for possible confounding by body size, models were adjusted for BMI Z-score at EDC measurement [16–18, 38, 39].
Results

The influence of EDC exposure across childhood and adolescence on the age of menarche was assessed among 200 Chilean girls born in 2002–2003. The median age at urine collection prior to the onset of breast development (B1) was 7.9 years and 11.2 years at Tanner 4 (Table 1). Proportion of samples with measurements above the limit of detection, as well as the geometric mean (95% CI) biomarker concentrations at B1 and B4 are reported in Additional file 1: Tables S1a and S1b. Analysis was restricted to the subset of 21 biomarkers with detectable concentrations at Tanner 1 and Tanner 4 in at least 75% of the girls. These 21 biomarkers included: 2,4-dichlorophenol, 2,5-dichlorophenol, benzophenone-3, BPA, MBP, MBzP, MCNP, MCOP, MCPP, MECCP, MEHHP, MEHP, MEOHP, MEP, methyl paraben, MHBP, MiBP, MiFP, propyl paraben, triclosan; excluded were: MNP, B-PB, BPF, BPS, and E-PB (see Abbreviation List; Additional file 1: Table S1a and S1b). For reference, geometric mean (95% CI) phenol and phthalate creatinine-adjusted urinary biomarker concentrations among U.S. females of a similar age range from the 2011–2012 National Health and Nutrition Examination Survey are reported in Additional file 1: Table S2. In both the U.S. and Chilean populations, most biomarker concentrations decreased with age (Additional file 1: Table S1a and S1b; Additional file 1: Table S2). The intra-

Table 1 Study population characteristics

| Characteristic                       | Distribution                  |
|--------------------------------------|-------------------------------|
| Age [years; median (range)]          |                               |
| At B1 EDC Measurement                | 7.9 (6.7–9.6)                 |
| At B4 EDC Measurement                | 11.2 (9.4–13.1)               |
| Attained Menarche during Study Category [count (%)] |                 |
| Yes                                  | 182 (91.0)                    |
| No                                   | 18 (9.0)                      |
| Age at Menarche [years; median (range)] |                   |
| BMI Z-score [median (range)]         |                               |
| At B1 EDC Measurement                | 0.5 (–2.2–2.4)                |
| At B4 EDC Measurement                | 0.5 (–2.7–2.2)                |
| BMI Category [count (%)]             |                               |
| At B1 EDC Measurement                |                               |
| Under-weight or Normal weight (<85th Percentile) | 147 (73.5)                  |
| Overweight or Obese (≥85th percentile) | 53 (26.5)                    |
| At B1 EDC Measurement                |                               |
| Under-weight or Normal weight (<85th Percentile) | 137 (68.5)                  |
| Overweight or Obese (≥85th percentile) | 63 (31.5)                    |
| Height Z-score [median (range)]      |                               |
| At B1 EDC Measurement                | –0.1 (–2.6–2.1)               |
| At B4 EDC Measurement                | 0.1 (–2.1–2.3)                |
| Maternal Education [count (%)]       |                               |
| Post-Secondary Education             | 46 (23.0)                     |
| No Post-Secondary Education          | 154 (77.0)                    |
individual correlation between phenol and phthalate biomarkers at B1 and B4 was moderate to low (Additional file 1: Table S3). The mean age of menarche was 12.0 years; the median age was similarly 12.0 years (95% CI: 11.9–12.2 years). At the time of analysis, 18 girls had not reached menarche or had dropped out of the cohort. Of those that achieved menarche during the course of the study, 10.5% (n = 21) reached menarche prior to the first detection of B4. The occurrence of menarche prior to B4 did not significantly modify the linear association between any biomarkers and the age of menarche in adjusted models. Therefore, B4 biomarker measurements for these 21 girls were included in all subsequent models. Biomarker concentrations at B1 were not significantly correlated with BMI Z-score. Similarly, most B4 biomarker concentrations were not correlated with B4 BMI Z-score, with the exception of monoethyl phthalate (MEP) and 2,5-dichlorophenol, which had moderate positive associations with BMI Z-score (ρ = 0.21 and ρ = 0.22, respectively). Additional study population characteristics are outlined in Table 1.

We did not detect a significant linear impact of average concentration across Tanner stages on the age of menarche for any biomarker (Table 2). However, the association between urinary biomarker concentrations and the timing of menarche was significantly modified by the Tanner stage at biomarker measurement for 2,5-dichlorophenol, benzophenone-3, monomethyl phthalate (MMP), and all of the metabolites of DEHP after adjusting for BMI Z-score and maternal education (Table 2). Further adjustment for mother’s age of menarche (≤11, 12, 13, ≥14 years) did not change the shape or strength of the associations between EDC biomarker levels and daughter’s age of menarche (Additional file 1: Tables S4 and S5). For ease of interpretation, and to identify potential non-linear influences, we evaluated the association between tertiles of each biomarker and the timing of menarche in adjusted models (Table 3; Fig. 1; T1=lowest tertile, T2=middle tertile, T3=highest tertile). Among the subset of biomarkers for which we did not detect significant effect modification by Tanner stage at measurement, we found a non-monotonic change in the timing of menarche between

| Table 2 Menarche hazard ratio (95% CI) associated with log(ng/ml) increase in each EDC biomarker across puberty |
|---------------------------------------------------------|
| Biomarker | Unadjusted Model | Adjusted Model | Interaction with Tanner stage* | Interaction with BMI | |
| 2,4-Dichlorophenol | 0.98 (0.87, 1.10) | 1.00 (0.89, 1.12) | 0.246 | 0.062 |
| 2,5-Dichlorophenol | 1.05 (0.97, 1.14) | 1.04 (0.95, 1.14) | 0.017* | 0.975 |
| Benzophenone-3 | 1.03 (0.97, 1.09) | 1.05 (0.99, 1.11) | 0.009** | 0.235 |
| BPA | 0.90 (0.78, 1.05) | 0.92 (0.79, 1.06) | 0.362 | 0.790 |
| MIBP | 0.95 (0.84, 1.07) | 0.96 (0.85, 1.08) | 0.565 | 0.396 |
| MMbP | 0.98 (0.87, 1.09) | 0.94 (0.84, 1.05) | 0.729 | 0.891 |
| MCNP | 0.95 (0.82, 1.10) | 0.91 (0.79, 1.05) | 0.392 | 0.797 |
| MCOP | 0.95 (0.81, 1.10) | 0.92 (0.78, 1.09) | 0.638 | 0.790 |
| MCP | 0.91 (0.80, 1.04) | 0.91 (0.79, 1.05) | 0.157 | 0.252 |
| ΣDEHP | 1.04 (0.88, 1.22) | 1.02 (0.87, 1.19) | 0.002** | 0.783 |
| MECPP | 1.05 (0.89, 1.24) | 1.02 (0.87, 1.20) | 0.004** | 0.855 |
| MEHP | 1.03 (0.89, 1.18) | 1.01 (0.88, 1.16) | 0.002** | 0.643 |
| MEOH | 1.01 (0.85, 1.20) | 1.01 (0.85, 1.20) | 0.000*** | 0.909 |
| ME | 1.02 (0.88, 1.19) | 1.01 (0.87, 1.16) | 0.004** | 0.852 |
| MEP | 1.10 (0.99, 1.23) | 1.09 (0.98, 1.21) | 0.177 | 0.033* |
| Methyl Paraben | 1.00 (0.94, 1.07) | 1.00 (0.94, 1.07) | 0.861 | 0.576 |
| MHBP | 1.02 (0.89, 1.16) | 1.02 (0.89, 1.17) | 0.486 | 0.488 |
| MHB | 1.04 (0.88, 1.23) | 1.04 (0.88, 1.24) | 0.426 | 0.920 |
| MMb | 1.02 (0.87, 1.19) | 1.01 (0.86, 1.19) | 0.955 | 0.671 |
| MIMP | 1.05 (0.93, 1.19) | 1.08 (0.97, 1.22) | 0.017* | 0.262 |
| Propyl Paraben | 0.99 (0.92, 1.05) | 0.99 (0.93, 1.05) | 0.495 | 0.160 |
| Triclosan | 0.98 (0.90, 1.07) | 1.00 (0.92, 1.08) | 0.956 | 0.033* |

*Accelarated failure time model adjusting for BMI Z-score, and maternal education
*p-value for interaction between continuous biomarker concentration and Tanner stage at biomarker measurement in adjusted models
**p-value for interaction between continuous biomarker concentration and BMI Z-score in adjusted models
†units in log(nmol/l) reflecting the log transformed summation of DEHP metabolite concentrations
*p < 0.05, **p < 0.01, ***p < 0.001
tertiles of monobenzyl phthalate (MBzP) across puberty (Table 3; Fig. 1). While there was a later age of menarche among the second tertile of MBzP relative to the first (HR: 0.70; 95% CI: 0.54, 0.93), the highest tertile was not significantly different from the lowest (Table 3; Fig. 1).

Increased B1 concentrations of 2,5-dichlorophenol and benzophenone-3 were associated with decreased time to menarche (Table 3). In contrast, higher B1 concentrations of the DEHP biomarkers mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono(2-ethyl-5-oxohexyl) phthalate (MEOHP), and mono(2-ethylhexyl) phthalate (MEHP) were associated with later menarche (Table 4). Girls in the highest tertile of B1 2,5-dichlorophenol concentration had an earlier age of menarche compared to

---

**Table 3** Menarche hazard ratio (95% CI) between tertiles of each EDC biomarker across puberty

| Biomarker       | Middle vs Lowest Tertile | Highest vs Middle Tertile | Highest vs Lowest Tertile | Trend \( p \)-value |
|-----------------|--------------------------|---------------------------|---------------------------|--------------------|
| 2,4-Dichlorophenol | 1.03 (0.79, 1.35)        | 1.01 (0.79, 1.30)         | 1.04 (0.80, 1.37)         | 0.701              |
| BPA             | 1.06 (0.81, 1.38)        | 0.86 (0.67, 1.11)         | 0.91 (0.70, 1.20)         | 0.695              |
| MBP             | 0.95 (0.74, 1.23)        | 1.00 (0.76, 1.31)         | 0.95 (0.69, 1.31)         | 0.749              |
| MBzP            | 0.70* (0.54, 0.93)       | 1.16 (0.88, 1.55)         | 0.82 (0.62, 1.08)         | 0.155              |
| MCNP            | 0.99 (0.77, 1.27)        | 0.91 (0.67, 1.23)         | 0.89 (0.67, 1.19)         | 0.433              |
| MCOP            | 0.94 (0.72, 1.22)        | 0.99 (0.75, 1.30)         | 0.93 (0.68, 1.27)         | 0.661              |
| MCPP            | 0.92 (0.67, 1.26)        | 0.84 (0.63, 1.13)         | 0.77 (0.57, 1.04)         | 0.116              |
| MEP             | 1.00 (0.74, 1.34)        | 1.20 (0.88, 1.62)         | 1.19 (0.90, 1.57)         | 0.212              |
| Methyl Paraben  | 0.96 (0.71, 1.29)        | 1.14 (0.84, 1.54)         | 1.09 (0.81, 1.47)         | 0.575              |
| MHP             | 0.94 (0.72, 1.23)        | 1.10 (0.88, 1.39)         | 1.04 (0.76, 1.41)         | 0.808              |
| MHiBP           | 0.98 (0.76, 1.26)        | 1.09 (0.86, 1.39)         | 1.07 (0.82, 1.39)         | 0.654              |
| MIBP            | 0.85 (0.63, 1.15)        | 1.13 (0.85, 1.50)         | 0.96 (0.74, 1.26)         | 0.763              |
| Propyl Paraben  | 0.83 (0.60, 1.13)        | 1.20 (0.85, 1.68)         | 0.99 (0.73, 1.33)         | 0.918              |
| Triclosan       | 0.85 (0.66, 1.10)        | 1.05 (0.84, 1.30)         | 0.90 (0.67, 1.20)         | 0.536              |

\( *p < 0.05, **p < 0.01, ***p < 0.001 \)

---

*Accelerated failure time model adjusting for BMI Z-score and maternal education; restricting to the subset of associations for which there was no significant interaction between Tanner stage at biomarker measurement and biomarker concentration on timing of menarche (\( p > 0.05 \))

*Trend evaluated by modeling the log(median) concentration within tertiles as a continuous variable

---

**Fig. 1** Median menarcheal age (95% CI) between tertiles of EDC biomarker concentrations across Tanner stages. Significant difference (\( p < 0.05 \)) between: tertiles 1 and 2 indicated by A, tertiles 2 and 3 indicated by B, and tertiles 1 and 3 indicated by C.
those in the lowest tertile (Table 5; HR: 1.58; 95% CI: 1.09, 2.29), corresponding to 4.09 months earlier median age of menarche (Fig. 2). The influence of benzophenone-3 and the DEHP metabolites on the relative time to menarche was less linear (Table 5; Fig. 2).

The median age of menarche was 4.10 months earlier among girls in the second tertile of B1 benzophenone-3 concentration compared to the lowest tertile (HR: 1.58; 95% CI: 1.12, 2.22), but the change in timing was not significant between the lowest and highest tertiles (Table 5). For all of the secondary oxidative DEHP biomarkers quantified (MEHHP, MECPP, and MEOHP), the median age of menarche was 6.57 to 7.37 months later among girls in the middle tertile relative to those in the lowest tertile of B1 concentration (Table 5). For MEHHP, girls in the highest tertile at B1 also had a significantly later age of menarche, but the median delay was not as great as that among girls in the second tertile (Table 5; Fig. 2).

A log(ng/ml) increase in B4 concentrations of MMP was associated with a faster time to menarche (Table 4)

**Table 4** Menarche hazard ratio (95% CI) associated with log(ng/ml) increase in biomarker stratified by Tanner stage

| Biomarker          | Tanner Stage | B1          | B4          |
|--------------------|--------------|-------------|-------------|
| 2,5-Dichlorophenol | 1            | 1.13* (1.01, 1.27) | 0.96 (0.85, 1.08) |
| Benzophenone-3     | 1            | 1.17** (1.06, 1.29) | 0.99 (0.91, 1.06) |
| ΣDEHP              | 1            | 0.77* (0.60, 0.98) | 1.24 (0.97, 1.57) |
| MECPP              | 1            | 0.79 (0.61, 1.01) | 1.24 (0.97, 1.58) |
| MEHHP              | 1            | 0.77* (0.62, 0.96) | 1.22 (0.98, 1.51) |
| MEHP               | 1            | 0.80* (0.65, 0.98) | 1.20 (0.98, 1.47) |
| MEOHP              | 1            | 0.78* (0.63, 0.97) | 1.20 (0.96, 1.50) |
| MMP                | 1            | 0.96 (0.81, 1.14) | 1.30** (1.10, 1.53) |

*a*Accelerated failure time model adjusting for BMI Z-score and maternal education; including an interaction between Tanner stage at biomarker measurement and concentration; restricted to subset of associations for which the interaction with the timing of biomarker measurement was significant (*p* < 0.05)

*b*Units in log(nmol/l) reflecting the log transformed summation of DEHP metabolite concentrations

*p* < 0.05, **p** < 0.01, ***p** < 0.001

**Table 5** Menarche hazard ratio (95% CI) between tertiles of biomarker stratified by Tanner stage at measurement

| Biomarker          | Tanner Stage | Middle vs Lowest Tertile | Highest vs Middle Tertile | Highest vs Lowest Tertile | Trendb (p-value) |
|--------------------|--------------|--------------------------|---------------------------|---------------------------|------------------|
| 2,5-Dichlorophenol | 1            | 1.35 (0.93, 1.98)        | 1.17 (0.81, 1.68)         | 1.58* (1.09, 2.29)       | 0.019*           |
| Benzenophenone-3   | 1            | 1.16 (0.79, 1.69)        | 0.79 (0.55, 1.14)         | 0.91 (0.62, 1.35)        | 0.521            |
| 1                  | 1.58** (1.12, 2.22) | 0.89 (0.60, 1.34)       | 1.41 (0.96, 2.06)         | 0.142                   |
| 4                  | 0.87 (0.61, 1.24)  | 1.07 (0.74, 1.54)       | 0.93 (0.63, 1.37)         | 0.743                   |
| ΣDEHP              | 1            | 0.43*** (0.31, 0.61)     | 1.56* (1.09, 2.25)        | 0.67* (0.46, 0.98)       | 0.140            |
| 4                  | 0.93 (0.64, 1.36)  | 1.52* (1.01, 2.28)      | 1.42 (0.93, 2.17)         | 0.083                   |
| MECPP              | 1            | 0.43*** (0.30, 0.62)     | 1.63** (1.15, 2.33)       | 0.71 (0.47, 1.05)        | 0.232            |
| 4                  | 0.92 (0.64, 1.34)  | 1.53* (1.02, 2.31)      | 1.41 (0.93, 2.15)         | 0.082                   |
| MEHHP              | 1            | 0.47*** (0.33, 0.68)     | 1.44 (1.00, 2.09)         | 0.68* (0.47, 0.99)       | 0.064            |
| 4                  | 1.05 (0.73, 1.52)  | 1.29 (0.87, 1.90)       | 1.36 (0.89, 2.06)         | 0.148                   |
| MEHP               | 1            | 0.78 (0.54, 1.14)        | 0.94 (0.64, 1.38)         | 0.73 (0.50, 1.09)        | 0.122            |
| 4                  | 1.05 (0.74, 1.49)  | 1.40 (0.93, 2.10)       | 1.47 (0.98, 2.20)         | 0.061                   |
| MEOHP              | 1            | 0.43*** (0.30, 0.62)     | 1.92*** (1.34, 2.75)      | 0.83 (0.59, 1.17)        | 0.313            |
| 4                  | 1.07 (0.73, 1.55)  | 1.30 (0.87, 1.95)       | 1.39 (0.91, 2.12)         | 0.120                   |
| MMP                | 1            | 1.31 (0.89, 1.93)        | 0.82 (0.55, 1.22)         | 1.07 (0.74, 1.56)        | 0.672            |
| 4                  | 0.98 (0.68, 1.42)  | 1.45* (1.01, 2.10)      | 1.42* (1.02, 1.99)        | 0.032*                  |

*a*Estimating Tanner stage-specific association between biomarker and age of menarche adjusting BMI Z-score and maternal education, including an interaction between biomarker tertile and Tanner stage; restricted to subset of associations for which the interaction with Tanner stage was significant (*p* < 0.05)

*b*Trend evaluated by modeling the log(median) concentration within tertiles as a continuous variable

*p* < 0.05, **p** < 0.01, ***p** < 0.001
HR: 1.30; 95% CI: 1.10, 1.53). The influence of B4 concentrations of MMP on the age of menarche was relatively linear. Among girls in the highest B4 concentration tertile, the median age of menarche was 3.15 months earlier than girls in the lowest MMP tertile (Table 5; HR: 1.42; 95%: 1.02, 1.99).

For MEP and triclosan, the influence on the age of menarche was significantly modified by age and sex-adjusted BMI Z-score (Table 2). The average effect of triclosan across various body sizes was negligible, whereas there was a shift towards earlier menarche among girls with higher concentrations of MEP (Table 2). Stratifying by BMI category, a log(ng/ml) increase in triclosan concentration was associated with earlier age of menarche (Table 6; HR: 1.16; 95% CI: 1.01, 1.34) among girls that were either overweight or obese (≥85th percentile BMI Z-score). Similarly, a log(ng/ml) increase in MEP among overweight or obese girls was associated with earlier menarche (HR: 1.24; 95% CI: 1.05, 1.47), with the median age of menarche 5.03 months earlier in the highest compared to the lowest tertile (Fig. 3). There was no significant association with either triclosan or MEP among girls that were normal weight.

**Discussion**

In this study, we report changes in the timing of menarche associated with earlier childhood and adolescent biomarker urinary concentrations of several phthalates and phenols. For most of these biomarkers, the strength of the association was dependent on the timing of biomarker measurement, suggesting specific periods of susceptible hormone-driven development. High childhood (Tanner 1) urinary concentrations of DEHP metabolites were associated with later menarche. In contrast, increased childhood levels of 2,5-dichlorophenol and benzophenone-3 were associated with early menarche. Increased adolescent (Tanner 4) concentrations of MMP were similarly associated with earlier menarche. This sensitivity to exposure window may partially explain some discordance between prior studies of childhood EDC exposure and the age of menarche, which evaluated biomarker concentrations at various ages [25–28].

Among this cohort of Latina girls, increased urinary concentrations of DEHP biomarkers during childhood were associated with later menarcheal age. High prepubertal concentrations of these biomarkers have been associated with decreased concentrations of adolescent androgens, suggesting DEHP may inhibit adrenal androgen synthesis in humans [29]. This anti-androgenic influence of DEHP is further supported by the later age of pubarche among girls with relatively high concentrations
of DEHP metabolites [42, 43]. Another mechanism by which childhood DEHP exposure may influence pubertal timing is through its influence on concentrations of IGF-1 and thyroid hormones [44–47]. DEHP may also act by modifying the production of luteinizing hormone and follicle-stimulating hormone, reducing estrogen formation, or through the activation of peroxisome proliferation-activated receptors [48]. Similar to our findings, one longitudinal study of German adolescents recently reported that higher urinary concentrations of DEHP metabolites from ages 8–10 years were associated with decreased odds of having reached menarche at subsequent visits [30]. Other studies have not reported the same association between urinary DEHP biomarker concentrations and age of menarche. A cross-sectional study of U.S. girls 12–16 years reported the summation of phthalate urinary biomarker concentrations was not associated with the onset of menarche [27]. A smaller cross-sectional study of Hispanic girls in Mexico City also did not report a significant influence of these exposures [28]. In contrast, greater concentrations of DEHP biomarkers between 7 and 15 years were associated with increased odds of earlier menarche within a cohort of Chinese girls [26]. Our study results suggest that the influence of the biomarkers was modified by pubertal stage at the time of exposure assessment, and suggested the correlation in DEHP biomarker concentrations across puberty was weak. Therefore, these disparate findings may partially reflect differences in exposure window.

In contrast to the influence of the DEHP biomarkers, increased concentrations of 2,5-dichlorophenol, benzophenone-3, and MMP were associated with earlier menarche. 2,5-dichlorophenol is the major biomarker of para-dichlorobenzene, a chemical used in moth repel- lants, room deodorants, and fumigants. Two prior studies of U.S. girls reported a similar association between 2,5-dichlorophenol and age of menarche, which is consistent with the estrogenic activity 2,5-dichlorophenol has demonstrated in vitro and in vivo [25, 27, 49]. The sunscreen agent benzophenone-3 has also been shown to have estrogenic characteristics, including exerting uterotrophic effects in rats, simulating proliferation of breast cancer cell lines, as well as binding and activating estrogen receptors [50, 51]. While these compounds may have a similar mechanism of action, prior studies did not report a significant association between benzophenone-3 and menarcheal age [25, 27]. In our study, only pre-pubertal concentrations of 2,5-dichlorophenol and benzophenone-3 were associated with earlier menarche. Conversely, MMP concentrations close to the onset of menarche were associated with earlier timing. Two studies of Chinese girls reported conflicting associations between MMP concentrations and pubertal timing [52, 53]. The parent compound of MMP, dimethyl phthalate (DMP), can be found in insect repellants and plastics. While no estrogenic effect of DMP has been demonstrated in vivo, concentrations of MMP among children 5–7 years have been inversely associated with concentrations of IGF-1, with no significant impact on thyroid function [54]. The potential influence on the regulation of growth and development suggests the need for further investigation into the impact of MMP, or its precursor DMP, on adolescent development.

BMI significantly modified the influence of both MEP and triclosan on age of menarche. An increase in either biomarker was only associated with earlier menarche among girls that were either overweight or obese. Among U.S. children, neither association was significantly modified by BMI; however, the association with MEP was in a similar direction among all girls [25, 27]. It is possible that these differences in effect modification by BMI are due to race/ethnicity disparities in adolescent body composition [55]. Compared to white U.S. girls, Asian and Hispanic adolescents have greater trunk fat placement independent of total body fat [55]. Furthermore, Hispanic girls tend to have higher percent body fat than white girls, adjusting for body size [56]. It is possible the action of MEP and triclosan may be
modified by elements of metabolic profile shaped by fat distribution, such as modulations in insulin resistance or leptin production [18, 57]. Alternatively, the observed statistical interaction with BMI may reflect an influence of MEP and triclosan on both adiposity and menarcheal age. Prenatal exposure to MEP has been associated with decreased childhood BMI Z-score [23], but this association has been inconsistent across populations [22]. In one cross-sectional study, triclosan exposure was similarly associated with a decrease in BMI and waist circumference among children [58], but this correlation was not observed in a second cross-sectional study [38].

Given the impact of childhood adiposity on pubertal timing [59–63], the potential influence of EDCs on adiposity raises important consideration of the direction of causation. Specifically, EDC exposure could have a direct effect on menarcheal age, or influence adiposity to impact pubertal timing, or influence pubertal timing to impact adiposity. These theories are not mutually exclusive, and should be addressed by follow-up studies.

One limitation to this study is that we cannot account for the influence of earlier EDC exposure on pubertal timing that may have partially confounded the observed associations due to consistent home environment. For example, there is indication that exposure to certain EDCs in utero, such as DEHP, may influence both childhood adiposity and pubertal timing [21–23, 28]. A second limitation is that while this study did measure urinary biomarkers at two developmental time points, concentrations in a single spot urine may not be representative of average exposure. Nonetheless, prior longitudinal assessments of EDC concentrations suggest that spot measurements can estimate relative EDC exposures over the course of several months to a year due to recurrent exposures [64–67]. A third important consideration is that these girls were primarily from low socioeconomic status families, which may have an exposure profile that is not representative of all children and adolescents. However, given the faster decline in menarcheal age among impoverished girls [6, 8, 9, 14, 15], the determinants of pubertal timing within this subset of the population is of particular public health concern. Finally, this study did not account for potential synergistic or antagonistic impacts of EDC co-exposures on pubertal timing. In addition to the studied biomarkers, exposure to other types of unmeasured EDCs, such as persistent organic pollutants, may have modified our observed associations with pubertal development. These interactions may contribute to the lack of reproducibility in the associations between EDC biomarkers and the onset of menarche across populations. Given the concurrence of EDCs in consumer products and the home environment [68], it is difficult to disentangle the independent influence of any single chemical on menarcheal age.

However, we hope these findings spur additional research into modifiable sources of EDC exposure during childhood and adolescence.

**Conclusions**

Exposure to certain phenols and phthalates during specific stages of pubertal development was associated with menarcheal age in Chilean girls. This study highlights the necessity of capturing critical windows of exposure during periods of rapid physiological change. Additionally, the unique associations observed in this cohort emphasize the need to integrate investigations from across the world to identify population-specific sensitivities, which can guide global health recommendations. As data collection in this longitudinal cohort continues, we plan to explore the impact of EDC exposure on additional facets of pubertal development, such as the onset of regular cycling. These shifts in pubertal timing may have both immediate psychological implications for these girls, and may indicate changes in the predisposition to adverse health in adulthood. Girls with early puberty have been shown to suffer from higher rates of adolescent depression, anxiety, and delinquent behavior [69–72]. Early onset of menarche has also been associated with increased risk of type-2 diabetes, cardiovascular disease, and cancer risk. Future studies will be necessary to directly link the variation in pubertal timing associated with early life EDC exposure to adult health, as well as the potential direct effect of childhood/adolescent EDC exposure on adult health independent of age of menarche.

**Additional file**

**Additional file 1:** Table S1a. Phthalate metabolite urinary concentrations corrected for specific gravity in a Chilean girls cohort (n = 200). Table S1b. Phenol biomarker urinary concentrations corrected for specific gravity in a Chilean girls cohort (n = 200). Table S2. Geometric mean (95% CI) creatinine-adjusted urinary EDC biomarker concentrations and age at measurement in 2011–2012 U.S. National Health and Nutrition Examination Survey among females 5 to 14 years. Table S3. Spearman correlation between EDC 5G-adjusted biomarker urinary concentrations (ng/ml) at B1 and B4 in Chilean cohort (n = 200). Table S4. Sensitivity analysis: menarche hazard ratio (95% CI) associated with log(ng/ml) increase in each EDC biomarker across puberty adjusting for mother’s age of menarche. Table S5. Sensitivity analysis: menarche hazard ratio (95% CI) associated with log(ng/ml) increase in biomarker stratified by Tanner stage adjusting for mother’s age of menarche. (DOCX 27 kb)

**Abbreviations**

- 24-DCP: 2,4-dichlorophenol; 25-DCP: 2,5-dichlorophenol; AFT: Accelerated failure time; B1: Tanner 1; B4: Tanner 4; BP-3: Benzophenone-3; BPA: Bisphenol A; B-PB: Butyl paraben; BPF: Bisphenol F; BPS: Bisphenol S; DEHP: di (2-ethylhexyl) phthalate; EDC: Endocrine disrupting chemical; EB: Ethyl paraben; MBP: Mono-n-butyl phthalate; MBzP: Monobenzyl phthalate; MCNP: Mono carboxyisononyl phthalate; MCOP: Mono carboxyisooctyl phthalate; MCPP: Mono-3-carboxypropyl phthalate; MECPP: Mono(2-ethyl-5-carboxyisooctyl) phthalate; MEHP: Mono(2-ethylhexyl) phthalate;
MEOHp: Mono(2-ethyl-5-oxohexyl) phthalate; MEP: Monoethyl phthalate; MHPB: Mono-hydroxybutyl phthalate; MIBP: Mono-isobutyl phthalate; MMP: Monomethyl phthalate; MNP: Mono-nonyl phthalate; M-PB: Methyl paraben; P-PB: Propyl paraben; TCS: Trioclan

Acknowledgements
We acknowledge Manori Silva, Ella Samandar, Jim Preau, Prabha Dwivedi, Xiaoliu Zhou, and Tao Jia who performed the measurements of phthalates and phenols biomarkers.

Funding
This work was supported by Public Health Service grant R01CA158313 from the National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services (to KBM).

Availability of data and materials
Please contact author for data requests.

Disclaimer
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Use of trade names is for identification only and does not imply endorsement by the CDC, the Public Health Service, or the US Department of Health and Human Services.

Authors' contributions
AMB, CC, AP, and KBM designed the research plan; CC, VM, and AP acquired the data; AMB, AMC, CC, AP, and KBM provided statistical analysis and wrote the paper; AMB, AMC, CC, VM, AP, and KBM provided critical revision of the manuscript for intellectual content; AMB and KBM had primary responsibility for final content. All authors approved the final manuscript as responsible for final content. AMB and KBM had primary responsibility for final content. All authors approved the final manuscript.

Ethics approval and consent to participate
The study protocol was approved by the Ethics Committee of the Institute of Nutrition and Food Technology, University of Chile. The study was also reviewed and approved by the IRB of the University of California, Los Angeles. Informed consent was obtained from all parents or guardians of children before the start of data collection.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, CA, USA. 2Institute of Nutrition and Food Technology, University of Chile, Santiago, Chile. 3Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA. 4Institute of Maternal and Child Research, University of Chile, Santiago, Chile.

Received: 14 September 2017 Accepted: 20 March 2018

Published online: 03 April 2018

References
1. He C, Zhang C, Hunter DJ, Hankinson SE, Louis GMB, Hediger ML, et al. Age at menarche and risk of type 2 diabetes: results from 2 large prospective cohort studies. Am J Epidemiol. 2009; https://doi.org/10.1093/aje/kwp372.
2. Lakshman R, Forouhi NG, Sharp SJ, Luben R, Bingham SA, Khaw K-T, et al. Early age at menarche associated with cardiovascular disease and mortality. J Clin Endocrinol Metab. 2009;94:4953–60.
3. Hisheh CC, Trichopoulos D, Katsoyanni K, Yiusa S. Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: associations and interactions in an international case-control study. Int J Cancer J Int Cancer. 1990;46:796–800.
4. Wyshak G, Frisch RE. Evidence for a secular trend in age of menarche. N Engl J Med. 1982;306:1033–5.
5. Euling SY, Selevan SG, Pescovitz OH, Skakkebaek NE. Role of environmental factors in the timing of puberty. Pediatrics. 2008;121(Suppl 3):S1567–71.
6. Ong KK, Ahmed ML, Dunger DB. Lessons from large population studies on timing and tempo of puberty (secular trends and relation to body size): the European trend. Mol Cell Endocrinol. 2006;254–255:8–12.
7. McDowell MA, Brody DJ, Hughes JP. Has age at menarche changed? Results from the National Health and nutrition examination surveys (NHANES) 1999–2004. J Adolesc Health Off Publ Soc Adolesc Med. 2007;40:227–31.
8. Morris DH, Jones ME, Schoemaker MJ, Ashworth A, Swardlow AJ. Secular trends in age at menarche in women in the UK born 1908–93: results from the breakthrough generations study. Paediatr Perinat Epidemiol. 2011;25:394–400.
9. Junqueira Do Lago M, Faerstein E, De Souza Lopes C, Wernicke GL. Pré-Saúde study (Rio de Janeiro, Brazil). Family socio-economic background modified secular trends in age at menarche: evidence from the Pré-Saúde study (Rio de Janeiro, Brazil). Ann Hum Biol. 2003;30:347–52.
10. Freedman DS, Khan LK, Srinivasan SR, Berenson GS. Relation of age at menarche to race, time period, and anthropometric dimensions: the Bogalusa heart study. Pediatrics. 2002;110:e43.
11. Chumlea WC, Schubert CM, Roche AF, Kuli HE, Lee PA, Himes JH, et al. Age at menarche and racial comparisons in US girls. Pediatrics. 2003;111:110–13.
12. Anderson SE, Must A. Interpreting the continued decline in the average age at menarche: results from two nationally representative surveys of U.S. girls studied 10 years apart. J Pediatr. 2005;147:53–60.
13. Wu T, Mendola P, Buck GM. Ethnic differences in the presence of secondary sex characteristics and menarche among US girls: the third National Health and nutrition examination survey, 1988–1994. Pediatrics. 2002;110:752–7.
14. Dossus L, Nkavkoff M, Bijon A, Fervers B, Buxton-Ruault M-C, Messene S, et al. Determinants of age at menarche and time to menstrual cycle regularity in the French E3N cohort. Ann Epidemiol. 2012;22:723–30.
15. Amigo H, Vásquez S, Bustos P, Ortiz G, Lara M. Socioeconomic status and age at menarche in indigenous and non-indigenous Chilean adolescents. Cad Saude Publica. 2012;28:977–83.
16. Buck Louis GM, Gray LE, Marcus M, Ojeda SR, Pescovitz OH, Witchel SF, et al. Environmental factors and puberty timing: expert panel research needs. Pediatrics. 2008;121(Suppl 3):S192–207.
17. Biró FM, Greenspan LC, Galvez MP. Puberty in girls of the 21st century. J Pediatr Adolesc Gynecol. 2012;25:289–94.
18. Kaplowitz PB. Link between body fat and the timing of puberty. Pediatrics. 2008;121(Suppl 3):S208–17.
19. Gone AC, Chappell VA, Fenton SE, Flaws JA, Nadal A, Prins GS, et al. EDC-2: the Endocrine Society’s second scientific statement on endocrine-disrupting chemicals. Endocr Rev. 2015;36:61–150.
20. Kim SH, Park MJ. Phthalate exposure and childhood obesity. Ann Pediatr Endocrinol Metab. 2014;19:69--75.
21. Buckley JP, Engel SM, Mendez DA, Richardson DB, Daniels JL, Calafat AM, et al. Prenatal phthalate exposures and childhood fat mass in a new York City cohort. Environ Health Perspect. 2016;124:507–13.
22. Valu D, Casas M, Romaguera D, Monfort N, Ventura R, Martinez D, et al. Prenatal phthalate exposure and childhood growth and blood pressure: evidence from the Spanish INMA-Sabadell birth cohort study. Environ Health Perspect. 2015;123:1022–9.
23. Buckley JP, Engel SM, Braun JM, Whayatt RM, Daniels JL, Mendez MA, et al. Prenatal phthalate exposures and body mass index among 4- to 7-year-old children: a pooled analysis. Epidemiol Camb Mass. 2016;27:449–58.
24. CDC. Fourth National Report on human exposure to environmental chemicals. Atlanta: Centers for Disease Control and Prevention National Center for Environmental Health Division of Laboratory Sciences; 2012.
25. Wolff MS, Pajak A, Pinney SM, Windham GC, Galvez M, Rybak M, et al. Associations of urinary phthalate and phenol biomarkers with menarche in a multiracial cohort of young girls. Reprod Toxicol Elmsford N. 2017;67:56–64.
26. Zhang Y, Cao Y, Shi H, Jiang X, Zhao Y, Fang X, et al. Could exposure to phthalates speed up or delay pubertal onset and development? A 1.5-year follow-up of a school-based population. Environ Int. 2015;83:34–9.
27. Burkle DE, Sircar K, Martin C. Exposures to endocrine-disrupting chemicals and age of menarche in adolescent girls in NHANES (2003-2008). Environ Health Perspect. 2012;120:1613–8.

28. Watkins DJ, Tellez-Rojo MM, Ferguson KK, Lee JM, Solano-Gonzalez M, Blank-Goldenberg C, et al. In utero and peripubertal exposure to phthalates and BPA in relation to female sexual maturation. Environ Res. 2014;134:233–41.

29. Mouritsen A, Frederiksen H, Sørensen K, Akgłaede L, Hagen C, Skakkebaek NE, et al. Urinary phthalates from 168 girls and boys measured twice a year during a 5-year period: associations with adrenal androgen levels and puberty. J Clin Endocrinol Metab. 2013;98:3555–64.

30. Kasper-Sonnemberg M, Wittecspe. J Wälk C, Koch HM, Wilhelm M. Pre- pubertal exposure with phthalates and bisphenol a and pubertal development. PLoS One. 2017;12:e0187922.

31. Corvalán C, Uauy R, Stein AD, Kain J, Martorell R. Effect of growth on cardiometabolic status at 4 y of age. Am J Clin Nutr. 2009;90:547–55.

32. Tanner J. Growth at adolescence. Oxford: Blackwell Scientific Publications; 1962.

33. Corvalán C, Uauy R, Stein AD, Kain J, Martorell R. Effect of growth on cardiometabolic status at 4 y of age. Am J Clin Nutr. 2009;90:547–55.

34. Hornung RW, Reed LD. Estimation of average concentration in the presence of nondetectable values. Appl Occup Environ Hyg. 1995;10:46–51.

35. Boeniger MF, Lowry LK, Rosenberg J. Interpretation of urine results used to assess chemical exposure with emphasis on creatinine adjustments: a review. Am Ind Hyg Assoc J. 1993;54:615–27.

36. Tyrrell J, Melzer D, Henley W, Galloway TS, Osborne NJ. Associations of urinary phenols with environmental exposure. Anal Chem. 2005;77:5407–13.

37. Silja MJ, Samandar E, Freau J, Reidy JA, Needham LL, Calafat AM. Quantification of 22 phthalate metabolites in human urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;860:106–12.

38. Lovekamp-Swan T, Davis BJ. Mechanisms of phthalate ester toxicity in the testis. Environ Health Perspect. 2003;111:133–45.

39. Persson BM, Astrid K, Versteegh L, Tuma W, Janssen CR. In vitro and in vivo estrogenicity and toxicity of p-, m-, and p-dichlorobenzene. Environ Toxicol Chem. 2003;22:329–35.

40. Schlumpf M, Cotton B, Cosscience M, Haller V, Steinmann B, Lichtensteiger W. In vitro and in vivo estrogenicity of UV screens. Environ Health Perspect. 2001;109:239–44.